Found 7 matching trials
Cold Induced Changes in White Adipose EARLY_PHASE1 An adaptation to a cold environment is a tendency to generate heat within o...
Show More Location
University of Kentucky Medical Center Center for Clinical and Translational Science
Learn More & Join Trial
Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL PHASE1 The goal of this clinical research study is to learn how PCI-32765 (ibrutin...
Show More Location
University of Texas MD Anderson Cancer Center
Learn More & Join Trial
Feasibility Study: Heavy Water Tissue Labeling Protocol NA Enrolled subjects undergo tissue labeling to evaluate the rate of collagen ...
Show More Location
Sasaki Advanced Aesthetic Medical Center
Learn More & Join Trial
Implementation and Validation of an Analytical Protocol for Measuring de Novo Lipogenesis in the Liver Using Stable Isotopes NA During this study, an analytical protocol for measuring hepatic de novo lip...
Show More Location
KU Leuven/ UZ Leuven
Learn More & Join Trial
Effect of Insulin Lowering on Lipogenesis PHASE1 The goal of this clinical trial is to compare a one-week course of diazoxid...
Show More Location
Columbia University Irving Medical Center
Learn More & Join Trial
Study of XNW5004 Tablets in Advanced Prostate Cancer PHASE2 Phase Ib A preliminary design of 2 cohorts is planned for this phase, with ...
Show More Location
Multiple Locations
Treatments Being Tested
XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone XNW5004 1200 mg BID in Combination with Docetaxel plus Prednisone XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO BID XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO, QDD XNW5004 800/1200 mg BID in Combination with Docetaxel plus Prednisone XNW5004 1200 mg, PO, BID (10-14 hours interval between two doses, taken with warm water); Enzalutamide 160 mg, PO, QD. Each treatment cycle consists of 4 weeks. Subsequent development plans will be determined based on preliminary study results. Learn More & Join Trial
Assessments of Adipogenesis, Lipid Turnover and Cellular Composition in Adipose Tissue in Response to Endurance Exercise NA The purpose of this research study is to study the effects of endurance exe...
Show More Location
AdventHealth Translational Research Institute
Learn More & Join Trial